MIND MEDICINE MINDMED INC (MNMD) Stock Price, Forecast & Analysis
NASDAQ:MNMD • CA60255C8850
MNMD Key Statistics, Chart & Performance
The current stock price of MNMD is 15.02 USD. In the past month the price increased by 24.34%. In the past year, price increased by 109.92%.
MNMD Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to MNMD. When comparing the yearly performance of all stocks, MNMD is one of the better performing stocks in the market, outperforming 93.9% of all stocks.
MNMD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MNMD. The financial health of MNMD is average, but there are quite some concerns on its profitability.
MNMD Financial Highlights
Over the last trailing twelve months MNMD reported a non-GAAP Earnings per Share(EPS) of -1.96. The EPS increased by 13.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -70.95% | ||
| ROE | -128.72% | ||
| Debt/Equity | 0.31 |
MNMD Forecast & Estimates
19 analysts have analysed MNMD and the average price target is 29.16 USD. This implies a price increase of 94.11% is expected in the next year compared to the current price of 15.02.
MNMD Ownership
MNMD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.65 | 985.228B | ||
| JNJ | JOHNSON & JOHNSON | 21.04 | 593.362B | ||
| MRK | MERCK & CO. INC. | 22.63 | 307.597B | ||
| PFE | PFIZER INC | 9.02 | 154.31B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.07 | 125.402B | ||
| ZTS | ZOETIS INC | 18.78 | 56.699B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.7 | 26.207B | ||
| VTRS | VIATRIS INC | 6.36 | 18.503B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.67 | 13.107B | ||
| AXSM | AXSOME THERAPEUTICS INC | 200.52 | 8.567B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MNMD
Company Profile
Definium Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in New York City, New York and currently employs 74 full-time employees. The company went IPO on 2015-05-04. Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The firm plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).
Company Info
MIND MEDICINE MINDMED INC
One World Trade Center, Suite 8500
New York City NEW YORK US
Employees: 74
Phone: 12122206633
MIND MEDICINE MINDMED INC / MNMD FAQ
Can you describe the business of MIND MEDICINE MINDMED INC?
Definium Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in New York City, New York and currently employs 74 full-time employees. The company went IPO on 2015-05-04. Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The firm plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).
What is the stock price of MIND MEDICINE MINDMED INC today?
The current stock price of MNMD is 15.02 USD. The price increased by 1.01% in the last trading session.
Does MNMD stock pay dividends?
MNMD does not pay a dividend.
What is the ChartMill technical and fundamental rating of MNMD stock?
MNMD has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for MIND MEDICINE MINDMED INC?
MIND MEDICINE MINDMED INC (MNMD) has a market capitalization of 1.48B USD. This makes MNMD a Small Cap stock.
Can you provide the upcoming earnings date for MIND MEDICINE MINDMED INC?
MIND MEDICINE MINDMED INC (MNMD) will report earnings on 2026-03-04, after the market close.